Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (6): 51-60.doi: 10.6040/j.issn.1671-7554.0.2019.423

Previous Articles    

Effect of Fugan Huaxian Decoction on TGF-β1/Smad signaling pathway in rats with hepatic fibrosis

XIAO Zhenghua1, YANG Hui2, LEI Wei3, YANG Jun3, YI Xu4, TAN Minmin5   

  1. 1. Department of Gastroenterology, Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou, China;
    2. Department of Neurology, the Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou, China;
    3. Grade 2016 Postgraduate, Guizhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou, China;
    4. Central laboratory of the Second Clinical Medical College of GuiZhou University of 〓山〓东〓大〓学〓学〓报〓(医〓学〓版)57卷6期〓-肖政华, 等.扶肝化纤汤对肝纤维化大鼠TGF-β1/Smad信号通路的影响〓\=-Traditional Chinese Medicine, Guiyang 550001, Guizhou, China;
    5. Department of Respiratory Medicine, the Second Clinical Medical College of GuiZhou University of Traditional Chinese Medicine, Guiyang 550001, Guizhou, China
  • Published:2022-09-27

PDF (PC)

78

Abstract: Objective To explorethe effect of Fugan Huaxian Decoction on transforming growth factor β1(TGFβ1)/Smad signaling pathway in rats with hepatic fibrosis(HF)and the mechanism of anti-hepatic fibrosis. Methods A total of 120 SD rats were randomly divided into control group, model group, colchicine group, and high, medium and low dose group of decoction. Except for the control group,the other groups established HF rat models of Qi deficiency, poison weakness and blood stasis under the guidance of traditional Chinese medicine(TCM)theory based on classical subcutaneous injection of carbon tetrachloride(CCl4). After 6 weeks, when the models were successfully established, the decoction groups received gastrogavage for 3 weeks, while the control group and model group were given equal volume of pure water for 3 weeks. Next day after the last gastrogavage, the serum aspartate aminotransferase(AST), alanine aminotransferase(ALT), albumin(ALB), hydroxyproline(Hyp),laminin(LN)and pre-collagen type Ⅲ(PⅢNP)levels were measured. The liver tissues were stained with HE and Mason stainings. The protein and mRNA expressions of TGF-beta1, Smad3 and Smad7 in liver tissues were detected with qRT-PCR and immunohistochemistry. Results Compared with the model group, decoction groups showed relieved hepatocyte injury, decreased collagen fiber proliferation, improvedhepatic fibrosis(χ2=54.722, P<0.01), and reduced proportion of liver collagen fibers(χ2=52.149, P<0.01). Compared with the control group, the model group had increased serum ALT(χ2=39.685, P<0.01), AST(F=659.984, P<0.01), Hyp(χ2=38.613, P<0.01), LN(χ2=50.057, P<0.01), PⅢNP(F=63.492, P<0.01), decreased ALB(χ2=51.908, P<0.01), increased expressions of TGF-β1(χ2=40.900, P<0.01), Smad3(χ2=38.253, P<0.01), TGF-β1 mRNA(F=92.304, P<0.01), Smad3 mRNA(F=119.563, P<0.01), and decreased Smad7(χ2=48.949, P<0.01)and Smad7 mRNA(F=42.120, P<0.01). Compared with the model group, the decoction groups inhibited the changes of the above indexes(P<0.01), especially the high dosage group(P<0.01). Conclusion The model of Qi deficiency, poison weakness and blood stasis complicated with HF was successfully established. Fugan Huaxian Decoction can protect hepatocytes, alleviate liver injury and inhibit HF, probably by regulatingthe expressions of TGF-beta1, Smad3 and Smad7.

Key words: Fugan Huaxian Decoction, TGF-β1/Smad signaling pathway, Hepatic fibrosis, Syndrome combination, Rat model

CLC Number: 

  • R574
[1] Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis[J]. Clin Chim Acta, 2006, 364(1): 33-60.
[2] 卢玮, 刘学恩, 庄辉.肝纤维化相关细胞因子和信号通路研究进展[J].中国病毒病杂志, 2016, 6(5): 385-390. LU Wei, LIU Xueen, ZHUANG Hui, et al.Advances in cytokines and signal pathways related to liver fibrosis[J]. Chinese Journal of Viral Diseases, 2016, 6(5): 385-390.
[3] Seifert L, Deutsch M, Alothman S, et al. Dectin-1 regulates hepatic fibrosis and hepatocarcinogenesis by suppressing TLR4 signaling Pathways[J]. Cell Rep, 2015, 13(9): 1909-1921.
[4] 韦冬珏, 张凤英, 周莹, 等.中医药联合干细胞抗肝纤维化的思路与进展[J].中华中医药学刊, 2019, 37(1): 76-81. WEI Dongjue, ZHANG Fengying, ZHOU Ying, et al.Thoughts and progress of combination of traditional Chinese medicine and stem cells in the treatment of liver fibrosis[J]. Chinese Archives of Traditional Chinese Medicine Brief Introduction, 2019, 37(1): 76-81.
[5] 马国珍,祁莲芳,田旭东,等.扶正化瘀抗纤方对肝硬化大鼠TGF-β1及PDGF表达的研究[J].中国民族民间医药,2018,27(23): 38-41. MA Guozhen, QI Lianfang, TIAN Xudong, et al. Effect of fuzheng huayu kangxian prescription on the expression of TGF-beta 1 and PDGF in rats with liver cirrhosis[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2018, 27(23): 38-41.
[6] 崔峻松,谭芊任,肖政华.扶肝化纤汤治疗慢性乙型病毒性肝炎肝纤维化临床研究[J].亚太传统医药,2017,13(4): 131-133. CUI Junsong, TAN Qianren, XIAO Zhenghua. Clinical study on the treatment of hepatic fibrosis in chronic viral hepatitis b with fugan huaxian decoction[J]. Asia-Pacific Traditional Medicine, 2017, 13(4): 131-133.
[7] 程明亮,杨长青.肝纤维化的基础研究及临床[M].2版.北京: 人民卫生出版社,2002: 20.
[8] 周玉平.肝纤维化病证结合动物模型评析[J].时珍国医国药,2011,22(6): 1504-1505. ZHOU Yuping. Evaluation and analysis of animal model of liver fibrosis syndrome combination[J]. Lishizhen Medicine and Materia Medica Research, 2011, 22(6): 1504-1505.
[9] 包剑锋,黄劲松,张永生,等.肝纤维化病证结合模型的研究思路[J].中华中医药,2012,30(4): 830-832. BAO Jianfeng, HUANG Jingsong, ZHANG Yongsheng, et al. Research thoughts on the model of combination of diseases and syndromes of liver fibrosis[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2012, 30(4): 830-832.
[10] 阎晶璐,薛晓兴,李君玲,等.肝纤维化肝气郁结证大鼠模型研究与证候时间窗方剂验证[J].北京中医药大学学报,2016,39(11): 893-901. YAN Jinglu, XU Xiaoxing, LI Junling, et al. Study on rat model of liver fibrosis with liver-qi depression syndrome and verification of syndrome time window prescription[J]. Journal of Beijing University of Traditional Chinese Medicine, 2016, 39(11): 893-901.
[11] 中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识[J].中华肝脏病杂志,2002,10(10): 327-328. Hepatic fibrosis group, Chinese Society of Hepatology. Consensus on diagnosis and efficacy evaluation of hepatic fibrosis[J]. Chinese Journal of Hepatology, 2002, 10(10): 327-328.
[12] 王丽春,赵连三,唐红,等.两种肝纤维化的组织学量化方法的实验研究[J]. 生物医学工程学杂志,2007, 24(1): 166-169. WANG Lichun, ZHAO Liansan, TANG Hong, et al.An experimental study of two histological quantitative methods for hepatic fibrosis[J]. Journal of Biomedical Engineering, 2007, 24(1): 166-169.
[13] Scharl A, Vierbuchen M, Conradt B, et al. Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffin-embedded breast cancer tissue using a monoclonal antibody[J]. Arch Gynecol Obstet, 1990, 247(2): 63-71.
[14] 黄烨,殷惠军,陈可冀.病证结合的基础研究[J].中国中西医结合杂志,2012,32(3): 299-303. HUANG Ye, YIN Huijun, CHEN Keji. Basic research on the combination of disease and syndrome[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2012, 32(3): 299-303.
[15] 颜琳琳,周利红,李琦.中医血瘀证动物模型研究概况[J].中医杂志,2014, 55(3): 255-258. YAN Linlin, ZHOU Lihong, LI Qi.A Survey of animal models of blood stasis syndrome in traditional Chinese medicine[J]. Journal of Traditional Chinese Medicine, 2014, 55(3): 255-258.
[16] 林志健,张冰,刘小清,等.中医证候动物模型评价研究[J].中华中医药杂志,2013, 28(8): 2217-2221. LIN Zhijian, ZHANG Bing, LIU Xiaoqing, et al. Evaluation of animal model of TCM syndrome[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2013, 28(8): 2217-2221.
[17] 马学惠.肝纤维化动物模型的造模方法[J].中华肝脏病杂志,1996,4(1): 58-60. MA Xuehui. Establishment of animal models of hepatic fibrosis[J].Chinese Journal of Hepatology, 1996, 4(1): 58-60.
[18] 聂珍贵,王姝,王世全,等.和肝汤对四氯化碳致小鼠肝纤维化的防治作用[J].时珍国医国药,2018,29(8): 1828-1830. NIE Zhengui, WANG Shu, WANG Shiquan, et al. Effect of hegan decoction on hepatic fibrosis induced by carbon tetrachloride in mice[J]. Lishizhen Medicine and Materia Medica Research, 2018, 29(8): 1828-1830.
[19] 杨艳,阎春英,陈旭,等.氯沙坦对实验性肝纤维化模型大鼠的作用[J].山东大学学报(医学版),2013,51(3): 27-31. YANG Yan, YAN Chunying, CHEN Xu, et al. Effects of losartan on experimental hepatic fibrosis in rats[J]. Journal of Shandong University(Health Sciences), 2013, 15(3): 27-31.
[20] Aram G, Potter JJ, Liu X, et al. Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration[J]. Hepatology, 2009, 49(3): 911-919.
[21] 苏洪佳, 陈国忠, 谢君艳.从中医脾虚“不能散精”论治肝硬化腹水[J].辽宁中医杂志,2019,46(1): 61-62. SU Hongjia, CHEN Guozhong, XIE Junyan. Treatment of Ascites due to Liver Cirrhosis from Spleen Deficiency “Cant Disperse Essence”[J]. Liaoning Journal of Traditional Chinese Medicine, 2019, 46(1): 61-62.
[22] Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis [J]. Exp CellRes, 2017, 352(2): 420-426.
[23] 刘国菊, 李从从, 李睿坤,等.转化生长因子β1在纤维化疾病发病中作用的研究进展[J].山东医药, 2018, 58(30): 106-108. LIU Guoju, LI Congcong, LI Ruikun, et al. Research progress on the role of transforming growth factor beta 1 in the pathogenesis of fibrosis[J]. Shandong Medical Journal, 2018, 58(30): 106-108.
[24] Marrone G, Shah VH, Gracia-sancho J.Sinusoidal communication in liver fibrosis and regeneration [J]. J Hepatol, 2016, 65(3): 608-617.
[25] Bi WR, Yang CQ, Shi Q. Transforming growth factor-beta1 induced epithelial-mesenchymal transition in hepatic fibrosis[J]. Hepatogastroenterology, 2012, 59(118): 1960-1963.
[26] Peng L, Jia X, Zhao J, et al. Substance P promotes hepatic stellate cell proliferation and activation via the TGF-β1/Smad-3 signaling pathway[J]. Toxicology and Applied Pharmacology, 2017, 329: 293-300.doi: 10.1016/j.taap.2017.06.020
[27] Yao QY, Xu BL, Wang JY, et al. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats[J]. BMC Complementary and Alternative Medicine 2012, 12: 156. doi: 10.1186/1472-6882-12-156.
[1] LI Shangzhi, LIU Haichun, WU Wenliang, CAO Cong, CHEN Yunzhen. Curative effect of mechanical stress in the treatment of nonunion [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 22-26.
[2] OUYANG Bing, PENG Zhongtian, WANG Pei. Expression and significance of cannabinoid receptor 1 and FAK in hepatic tissues of schistosomal hepatic fibrosis mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 11-14.
[3] LIU Jinwei1, LIU Haichun1, WU Wenliang1, CHEN Liang2, LI Shangzhi1, CAO Cong1, CHEN Yunzhen1. A femoral osteoporotic nonunion model established with an adjustable external fixator in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 33-36.
[4] MENG Xiangji, PANG Qi, DING Feng, XIN Tao, YANG Hongan. Establishment of PD rat model by injecting Taclo sterically and directionally into striatum [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 16-18.
[5] WANG Wei, CHANG Kang, LI Xiaodong, HAO Guimin. Effect of insulin sensitizer on the expression of insulin receptor substrate in endometrium of rats with polycystic ovarian syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(12): 24-29.
[6] YANG Yan1, YAN Chun-ying1, CHEN Xu2, LIN Xiao-yan3, WANG Lai-cheng4, SHI Jun1. Effect of losartan on the rat model of experimental hepatic fibrosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 27-31.
[7] YANG Yan1, WANG Xiao-hua2, FAN Xiao-sheng3. Grape seed proanthocyanidin  extract in the prevention
of rat liver fibrosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 11-.
[8] DONG Xiang-qian1, DUAN Li-ping1, LIANG Bing1, LI Shu-an1, LIU Bo2, ZHAN Er-yi2, SONG Jing-ling3, YANG Zhi-wei4, JIN De-guang4, MA Lan-qing1. A stereological study of Panax notoginseng saponin monomers Rg1 and Rb1 in inhibiting hepatic fibrosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 85-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd